Mark Cuban, Mark Cuban Cost Plus Drug Company, on bringing transparency to pharmacy
Subscribe for your weekly fix of health tech stories, wherever you get your news: Medium, Twitter, Apple, or Spotify. Our guest on this episode is Mark Cuban. In addition to a storied business career that includes owning the NBA’s Dallas Mavericks and a role on ABC’s Shark Tank, Mark is the founder and lead investor in the Mark Cuban Cost Plus Drug Company, a generic pharmaceutical distributor that prices medications at cost, plus a 15% administrative markup and any relevant pharmacy and shipping fees. Founded in early 2022, over 1.7M patients have signed up for the service in their first year, and Cost Plus Drugs now offers over 1,000 generic medications for purchase on their website. Mark founded the company with CEO Dr. Alex Oshmyansky, a pediatric radiologist who originally tried to start an organization similar to Cost Plus Drugs as a non-profit, before pivoting and convincing Mark to be his partner. Thanks for reading The Pulse Podcast, by Wharton Digital Health! Subscribe for fr
Subscribe for your weekly fix of health tech stories, wherever you get your news: Medium, Twitter, Apple, or Spotify. Our guest on this episode is Mark Cuban. In addition to a storied business career that includes owning the NBA’s Dallas Mavericks and a role on ABC’s Shark Tank, Mark is the founder and lead investor in the Mark Cuban Cost Plus Drug Company, a generic pharmaceutical distributor that prices medications at cost, plus a 15% administrative markup and any relevant pharmacy and shipping fees. Founded in early 2022, over 1.7M patients have signed up for the service in their first…
related reading
- Cost Plus Drugs - Wikipediaen.wikipedia.org
- Inside the Mafia of Pharma Pricing - BIG by Matt Stollerthebignewsletter.com
- How pharmacies, drug makers, PBMs and health plans are benefiting from your Rx benefits!healthtechstack.io
- GoodRx - Wikipediaen.wikipedia.org
- Understanding Drug Pricing from Divergent Perspectives: State of Washington Prescription Drug Pricing Analysis - 3 ∆XIS Advisors3axisadvisors.com
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- Pharma Virumque | Slate Star Codexslatestarcodex.com
- How PBMs can use private-labelled drug products as a great escape from anti-steering policies - 46brooklyn Research46brooklyn.com
- PBM aka Perfect Business Model (Part 1)substack.com
- Battle between Vertex, insurers leads to crushing CF drug costsstatnews.com
- The Fiduciary Obligation to Avoid 56,000% Markups on Rxgottwals.substack.com
- TrumpRxtrumprx.gov